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2Abstract 
Ciprofloxacin (CIP) is a poorly soluble drug that also displays poor permeability. Attempts to 
improve the solubility of this drug to date have largely focused on the formation of crystalline 
salts and metal complexes. The aim of this study was to prepare amorphous solid dispersions 
(ASDs) by ball milling CIP with various polymers. Following examination of their solid state 
characteristics and physical stability, the solubility advantage of these ASDs was studied, and 
their permeability was investigated via parallel artificial membrane permeability assay 
(PAMPA). Finally, the minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) of the ASDs were compared to those of CIP. It was discovered that acidic 
polymers, such as Eudragit L100, Eudragit L100C==, Carbopol and HPMCAS, were necessary 
for the amorphization of CIP. In each case, the positively charged secondary amine of CIP was 
found to interact with carboxylate groups in the polymers, forming amorphous polymeric drug 
salts. Although the ASDs began to crystallize within days under accelerated stability conditions, 
they remained fully XCray amorphous following exposure to 90% RH at 25 oC, and 
demonstrated higher than predicted glass transition temperatures. The solubility of CIP in water 
and simulated intestinal fluid was also increased by all of the ASDs studied. Unlike a number of 
other solubility enhancing formulations, the ASDs did not decrease the permeability of the drug. 
Similarly, no decrease in antibiotic efficacy was observed, and significant improvements in the 
MIC and MBC of CIP were obtained with ASDs containing HPMCASC") and HPMCASCMG. 
Therefore, ASDs may be a viable alternative for formulating CIP with improved solubility, 
bioavailability and antimicrobial activity. 
Keywords: ciprofloxacin, amorphous solid dispersion, polymer, polymeric drug salts, solubility, 
PAMPA. 
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3Introduction 
Ciprofloxacin (CIP) is a second generation fluoroquinolone antibiotic with a wide spectrum of 
activity. Anhydrous CIP usually exists as a zwitterion, as shown in Figure 1; however, it can 
convert to the unionized form when heated to approximately 270 oC or spray dried in a mixture 
of ethanol and water.1 In solution, the carboxylic acid and piperazine of CIP can ionize, 
depending on the pH of the surrounding media. In the neutral pH range CIP is largely 
zwitterionic and has an overall neutral charge, making it practically insoluble in aqueous media. 
The solubility of CIP in water has been reported as 0.06 and 0.08 mg/mL at 25 oC and 37 oC 
respectively.2 CIP is also poorly soluble in other common solvents such as ethanol, methanol, 
propanol, acetone and chloroform.3 CIP is also known to display poor permeability, and 
therefore may be considered as a class IV Biopharmaceutics Classification System (BCS) drug.4 
Figure 1. Structure of zwitterionic ciprofloxacin. 
Due to the strength of its intermolecular interactions, the dissociation of CIP’s crystal lattice 
upon addition to water is hindered. The solubility of the drug can therefore be improved by 
disrupting its crystal lattice via salt formation or amorphization.5 Salt formation is the most 
frequently used process for improving the solubility of acidic and basic drugs, and is also 
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claimed to be the most effective.6 For this reason it has been the main focus of research aimed at 
improving the solubility of CIP. The hydrochloride salt of CIP is available on the market as a 
tablet for oral administration. This form of the drug has been reported to have a solubility of 
approximately 42 mg/mL in water at 37 oC.7 However, due to the common ion effect, the 
solubility of HCl salts is decreased in the stomach.8 The lactate salt of CIP is available 
commercially as a solution for infusion, and has an aqueous solubility of just over 100 mg/mL.9 
Novel CIP salts have also been produced using malonic, tartaric and oxalic acid,10 mesylic, 
gluconic and glycolic acid,11 and saccharin.12 All of these salts showed an improvement in 
solubility compared to the pure drug. As an alternative to small molecules, polymers may be 
used as counter ions in pharmaceutical salts. Willis et al found that the extent and rate of 
methapyrilene release in simulated gastric and intestinal fluid was improved by the formation of 
drug-polymer salts, in which the amine group of the drug and carboxyl groups of the polymer 
interacted.13 
Another method for improving the aqueous solubility of drugs is amorphization. The amorphous 
form does not possess long range order, and is the most energetic solid state.14 It is therefore 
more soluble than the crystalline form, as less energy is required to enter solution.15 The 
production of amorphous and partially amorphous pure CIP by various techniques was recently 
described by our group. This was a challenging task, as the poor solubility and thermal 
degradation of CIP limit the techniques that can be used to amorphize it.1   
A major disadvantage of amorphous formulations is that they are intrinsically unstable and prone 
to crystallization.14 The most common approach taken to overcome the poor stability of 
amorphous drugs is to formulate them as amorphous solid dispersions (ASDs). ASDs consist of 
an amorphous dispersion of a drug in a solid carrier, where the carrier is either a small molecule 
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or polymer. The drug should ideally be molecularly dispersed.16 The carrier used to form an 
ASD must be chosen carefully in order to maximize the stability and solubility of the product. 
The physical stability of an ASD is improved if there are interactions between the components, 
e.g. hydrogen bonding and acid-base interactions. This reduces the molecular mobility of the 
drug and increases the energy required for crystallization.17 ASDs also enable faster drug 
dissolution, often resulting in supersaturation. The polymers present in an ASD help to prevent 
crystallization and precipitation of the drug in solution, and thus prolong this supersaturated 
state.18 
Despite the benefits of amorphous formulations, there is very little information in the literature 
regarding the formation of CIP ASDs. However, the production of amorphous salts of CIP and 
succinic acid with a 1:1 and 2:1 stoichiometry has previously been described by Paluch et al. 
These salts increased the solubility of CIP in water at 37 oC by over 300 and 600 times 
respectively.2 Other amorphous formulations of CIP which have been produced include 
nanoplexes formed using dextran sulfate,19 and microparticles containing chitosan and dextran.20 
Due to the lack of research in this area, the primary aim of this study was to prepare a number of 
solid dispersions of CIP with various polymers by ball milling, and to perform a comprehensive 
analysis of the successful ASDs.  The solid state properties of the samples were first 
investigated, in particular the nature of their drug-polymer interactions and thermal stability. As 
previously mentioned, a major issue associated with amorphous formulations is their poor 
physical stability, however this can be counteracted to some degree by the use of polymers with 
high Tg’s that interact specifically with the drug. The stability of the ASDs during dynamic vapor 
sorption (DVS) analysis and under accelerated conditions was therefore examined in order to 
determine their resistance to crystallization. 
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Another major goal of this study was to determine the effect of ASD formation on the 
biopharmaceutical properties of CIP, specifically its solubility, permeability and antimicrobial 
activity, and how these characteristics are connected. ASDs have been found to increase the 
solubility of drugs via supersaturation, while maintaining a constant permeability. In contrast, the 
solubility advantage obtained with formulations containing cyclodextrins, surfactants and 
cosolvents is negatively correlated with permeability.21 The solubility of crystalline CIP and the 
ASDs was therefore investigated in water and biorelevant media, and their permeability was 
compared using parallel artificial membrane permeability assay (PAMPA), to discover whether a 
similar relationship exists between the solubility and permeability of these preparations. Finally, 
it was of interest to determine whether the formulation of CIP as an ASD affected its 
antimicrobial activity, which should also be related to permeability. Therefore, the minimum 
inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of CIP and the 
ASDs were measured in a number of bacterial species. 
 
Materials and Methods 
Materials 
Anhydrous ciprofloxacin (CIP) was obtained from Carbosynth Limited, Berkshire, UK. 
Ciprofloxacin hydrochloride (CIP HCl) salt was kindly donated by Hemofarm, Serbia. The 
following polymers were used to form solid dispersions with CIP: Polyvinylpyrrolidone K17 
(PVP, Plasdone® C-15, ISP Technologies, New Jersey, USA); polyvinylalcohol (PVA, 98% 
hydrolyzed, Mw 13000–23000, Sigma-Aldrich, St. Louis, Missouri); methacrylic acid methyl 
methacrylate copolymer (Eudragit® L100, Evonik Röhm GmbH, Darmstadt, Germany); 
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methacrylic acid ethyl acrylate copolymer (Eudragit® L100-55, Evonik Röhm GmbH, 
Darmstadt, Germany); poly(acrylic acid) (Carbopol® 981, BF Goodrich, Ohio, USA); 
hydroxypropyl methylcellulose acetate succinate grades LG and MG (HPMCAS-LG and 
HPMCAS-MG, Shin-Etsu Chemical Co., Ltd, Tokyo, Japan); polyvinyl caprolactam-polyvinyl 
acetate-polyethylene glycol graft copolymer (Soluplus®, BASF SE, Ludwigshafen, Germany); 
and polyethylene glycol 4000 (PEG 4000, BDH Ltd, Poole, England). 
Fasted state simulated gastric fluid (FaSSGF) was produced by adding 60 mg SIF® Powder 
Original (biorelevant.com, Surrey, UK) to one liter of FaSSGF HCl solution, consisting of 34 
mM NaCl adjusted to pH 1.6 with HCl. Fasted state simulated intestinal fluid (FaSSIF) was 
produced by adding 2.24 g SIF® Powder Original to one litre of FaSSIF phosphate buffer, 
consisting of 19.5 mM NaOH, 25 mM NaH2PO4·H2O and 106 mM NaCl, adjusted to pH 6.5 
with NaOH. NaOH pellets were obtained from Riedel-de Haën®, Seelze, Germany, 
NaH2PO4·H2O from Merck, Darmstadt, Germany and NaCl from Sigma-Aldrich Ireland Ltd., 
Arklow, Ireland. Dodecane, triethylamine, lecithin (L-α-phosphatidylcholine, Type XVI-E) and 
phosphate buffered saline (PBS) tablets were obtained from Sigma-Aldrich Ireland Ltd., Arklow, 
Ireland. Brain-heart infusion (BHI) broth was purchased from bioMérieux (Marcy l’Étoile, 
France). Plates with Columbia agar supplemented with sheep blood were obtained from Oxoïd 
(Dardilly, France). All other chemicals and solvents were of analytical grade. 
Methods 
Ball Milling 
CIP was first milled with PVP at a concentration of 10–95% (w/w). Solid dispersions of CIP 
with Eudragit® L100, Eudragit® L100-55, Carbopol® 981, HPMCAS-LG, HPMCAS-MG, 
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PVA, Soluplus® and PEG 4000 were also formed using 20–60% (w/w) polymer. For each 
sample, milling was performed at room temperature using a Retsch® planetary ball mill PM 100 
(Haan, Germany). The only exception to this was the CIP/HPMCAS-LG and HPMCAS-MG 
ASDs, which were milled at 2–5 oC. 2 g of powder was added to 50 mL stainless steel grinding 
bowls. The three stainless steel milling balls were 20 mm in diameter and weighed 32 g each. 
The powder mixtures were each milled for 4–6 hours in total, in intervals of 15 min with 10 min 
breaks in between. At 1, 2, 4 and 6 hours, small samples of powder were taken for analysis by 
powder X-ray diffraction.  
Powder X-ray Diffraction (PXRD) 
PXRD was performed at room temperature using a benchtop Rigaku MiniflexII X-ray 
diffractometer (Tokyo, Japan) and a Haskris cooler (Illinois, USA). The measurements were 
carried out in reflectance mode. The samples were scanned from 5 to 40 2θ degrees in steps of 
0.05. A scan rate of 0.05o per second and signal collection time per step of 1 s were used. The 
tube (Cu, 1 kW normal focus) output voltage and current were 30 kV and 15 mA, respectively. 
Solid State Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR was performed using a Spectrum One FT-IR Spectrometer (Perkin Elmer, Connecticut, 
USA) equipped with Spectrum Software version 6.1. A spectral range of 450–4000 cm-1, 
resolution of 4 cm-1, scan number of 10 and scan speed of 0.2 cm/s were used. KBr disks were 
produced by direct compression, using a pressure of approximately 10 bar for 1 min. A sample 
loading of 1% (w/w) was used. Physical mixtures (PMs), which were prepared by blending 
together the drug and polymers in the same ratio as in the ASDs with a mortar and pestle, were 
also analyzed for comparison. 
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Differential Scanning Calorimetry (DSC) 
DSC was carried out using a Mettler Toledo DSC (Schwerzenbach, Switzerland). The purge gas 
was nitrogen. Approximately 5–10 mg samples were analyzed in sealed 40 µL aluminum pans 
with pierced lids. The ASDs were first heated from 25 to 70–100 oC to remove any water present 
in the powder. When cool, the samples were reheated from 25 to 300 oC at a rate of 10 oC/min. 
Mettler Toledo STARe software (version 6.10) was used to analyze the thermograms. 
Temperature-Modulated Differential Scanning Calorimetry (StepScan
TM
) 
A PerkinElmer Diamond DSC (Waltham, MA, USA) and ULSP B.V. 130 cooling system (Ede, 
Netherlands) were used to detect the Tg’s of the ASDs. A nitrogen gas flow of 40 mL/min was 
controlled with a PerkinElmer Thermal Analysis Gas Station. The instrument was calibrated for 
temperature and heat flow using indium standards. Approximately 5 mg samples were analyzed 
in 18 μL aluminum pans with sealed lids. Samples were heated at 5 oC/min in steps of 2 oC. 
Between each step the temperature was held constant for 1 min. The specific heat of the glass 
transition was calculated from the enthalpy flow using the area algorithm. 
Calculation of Theoretical Glass Transition (Tg) Values with Gordon-Taylor Equation 
The theoretical Tg’s of the ASDs were calculated using the Gordon-Taylor equation:
22,23 
 =
	


	

          (1) 
where K is approximately equal to 
 ≈ 

           (2) 
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w1 and w2 are the weight fractions, Tg1 and Tg2 are the glass transition temperatures, and ρ1 and 
ρ2 are the densities of the two components. The Tg of pure amorphous CIP was previously 
determined as 86.7 oC,1 while the Tg’s of the polymers were obtained from literature: Eudragit 
L100, 130 oC;24 Eudragit L100-55, 96 oC;25 HPMCAS-LG, 119 oC;26 and HPMCAS-MG, 120 
oC.26 The average density values for the various components were also obtained from literature: 
CIP, 1.5 g/cm3;1 Eudragit L100, 0.84 g/cm3;27 Eudragit L100-55, 0.83 g/cm3;28 and HPMCAS-
LG  and HPMCAS-MG, 1.29 g/cm3.29 The Tg’s predicted by the Gordon-Taylor equation were 
then compared to the experimental values measured by DSC. 
Thermogravimetric Analysis (TGA) 
TGA was carried out on the ASDs using a Mettler TG50 measuring module coupled to a Mettler 
Toledo MT5 balance (Schwerzenbach, Switzerland). Approximately 8–10 mg samples were 
analyzed in open aluminum pans, using nitrogen as the purge gas. Samples were heated from 25 
to 300 oC at a rate of 10 oC/min. Mettler Toledo STARe software (version 6.10) was used to 
analyze the thermograms. 
Dynamic Vapor Sorption (DVS) 
DVS studies were carried out using an Advantage-1 automated gravimetric vapor sorption 
analyzer (Surface Measurement Systems Ltd., London, UK). The temperature was maintained at 
25.0 ± 0.1 °C. Approximately 10 mg of ASD was added to the sample basket and placed in the 
instrument. The samples were equilibrated at 0% relative humidity (RH) until a constant mass 
was obtained (dm/dt ≤ 0.002 mg/min). The reference mass was recorded and sorption-desorption 
analysis was then carried out between 0 and 90% RH, in steps of 10% RH. At each stage, the 
sample mass was equilibrated (dm/dt ≤ 0.002 mg/min for at least 10 min) before the RH was 
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changed. An isotherm was calculated from the complete sorption and desorption profile. 
Following DVS analysis the samples were analyzed by PXRD in order to detect any 
crystallization. 
Accelerated Stability Study 
A stability study of the ASDs was conducted under accelerated storage conditions of 40 oC and 
75% RH. Samples of each powder were taken every 2–3 days for a period of 2 weeks.  PXRD 
was used to determine whether crystallization had occurred in any of the samples. 
Dynamic Solubility Studies 
10–20 mL of water, FaSSIF or FaSSGF was added to 40 mL glass vials.  These were placed into 
jacketed beakers connected to a Lauda M12 water bath (Lauda-Königshofen, Germany) and 
allowed to equilibrate to 37 oC. A quantity of pure drug or ASD, in excess of the expected 
saturated solubility (50–225 mg, depending on the sample), was added to the stirred vials. 
Samples were drawn from the vials at specific time points over a 2 hour period. These aliquots 
were filtered with 0.45 µm PTFE membrane filters (VWR, USA). The filtered solutions were 
then diluted with a 2.45 g/L solution of phosphoric acid, previously adjusted to pH 3.0 with 
triethylamine. The concentration of CIP in each of the diluted samples was determined by UV 
spectrophotometry. The solubility studies were repeated at least in triplicate with each medium. 
The pH of the solutions was measured before the addition of the samples and at the end of the 2 
hour study using a Thermo Orion 420A+ pH meter (Thermo Scientific, Hampshire, UK). The 
solid material left in the vials at the end of the studies was filtered and analyzed by PXRD. 
UV Spectrophotometry 
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UV analysis was carried out using a Shimadzu UV-1700 PharmaSpec UV-vis spectrophotometer 
(Shimadzu Corp., Kyoto, Japan). Quartz cells with a 1 cm optical path length were used for all 
measurements. UV absorbance was measured at 278 nm. The instrument was first blanked using 
a 2.45 g/L solution of phosphoric acid, previously adjusted to pH 3.0 with triethylamine. This 
buffer was also used to produce a range of concentrations of pure CIP, in order to construct a 
calibration curve. 
Parallel Artificial Membrane Permeability Assay (PAMPA) 
Permeability studies were carried out using the Lipid-PAMPA method described by Merck 
Millipore.30 A 96-well MultiScreen Filter Plate (Millipore Corporation, Billerica, MA, USA), 
with underdrain removed, was used as the donor plate, and a 96-well MultiScreen Transport 
Receiver Plate (Millipore Corporation, Billerica, MA, USA) as the acceptor plate. Solutions of 
CIP, CIP HCl, CIP/Eudragit L100, CIP/HPMCAS-LG and CIP/HPMCAS-MG in PBS pH 7.4 
and 6.4, at concentrations of 50–125 µg/mL, were prepared. 300 µL of PBS pH 7.4 was added to 
each well of the acceptor plate. 5 µL of a 1% (w/v) solution of lecithin in dodecane was added to 
the filter within each donor well to form an artificial membrane. 150 µL of the drug solutions 
were immediately added to each well of the donor plate in triplicate. The donor plate was then 
placed into the acceptor plate and incubated at room temperature for 16 hours. Following 
incubation, the contents of each well in the acceptor plate was diluted 1:4 with HPLC mobile 
phase and filtered with 0.45 µm PTFE membrane filters (VWR, USA). The concentration of CIP 
in each sample was then measured using HPLC. 
The effective permeability (Pe) of the samples was calculated using the following equation 
reported by Wohnsland and Faller:31 
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Pe = −ln	(1 − r)  () where r = 
[ !]##$%&'(
[ !])*+,-,.(,+/
     (3) 
VD and VA are the volumes of the donor and acceptor compartment, respectively, in cm
3, t is the 
incubation time in seconds, and A is the active surface area of the membrane (equal to the 
membrane area multiplied by the porosity ratio. For Millipore MultiScreen Permeability Filter 
Plate membranes this is equal to 0.24 cm2 x 100%, or 0.24 cm2).30 [Drug]Acceptor is the 
concentration of the drug in the acceptor compartment at the end of the assay. [Drug]Equilibrium  is 
determined by measuring the concentration of a reference solution, containing the drug at the 
theoretical equilibrium concentration (the overall concentration of the donor and acceptor 
solutions combined).32 Given that the acceptor and donor compartments used in this study had a 
volume of 150 µL and 300 µL respectively, the equilibrium concentration of the drug should 
theoretically be one-third of that of the original solution added to the donor well. 
High Performance Liquid Chromatography (HPLC) 
The content of CIP was measured with a Shimadzu® 10Avp HPLC system (Kyoto, Japan). A 
Luna 5u C8 column, with a length of 250 mm, internal diameter of 4.6 mm and 5 µm particle 
size, was used. The mobile phase consisted of 13 volumes of acetonitrile and 87 volumes of a 
2.45 g/L solution of phosphoric acid, previously adjusted to pH 3.0 with triethylamine. An 
injection volume of 10 µL and flow rate of 1.5 mL/min for 15 min was used. The separation was 
carried out at room temperature. A Shimadzu SPD-10Avp UV-vis Detector at 278 nm was used 
to detect the drug. 
Bacterial Studies 
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Bacterial studies were carried out on the following bacterial strains: (1) Staphylococcus aureus 
ATCC 25923, (2) Escherichia coli ATCC 25922, (3) Pseudomonas aeruginosa ATCC 27853 
and (4) Klebsiella pneumoniae DSM 16609. The bacteria were cultured on Columbia agar 
supplemented with sheep blood. The inoculum was prepared as described previously.33 The 
density of the microorganism suspension was adjusted to equal that of the 1.1 McFarland 
standard for S. aureus, and the 0.5 McFarland standard for P. aeruginosa, E. coli and K. 
pneumoniae. The former suspension was further diluted 100-fold with BHI medium, while the 
latter were diluted 10-fold. 
The Minimum Inhibitory Concentrations (MICs) of CIP and the ASDs were determined using 
the broth microdilution method described by Umerska et al.33 Several two-fold dilutions of the 
samples in BHI medium were prepared in order to obtain the desired concentration range. 50 µL 
of the bacterial suspension in BHI broth was then added to a well containing 50 µL of test 
sample or a control. The samples were incubated for 24 hours at 37 °C. All MIC assays were 
performed in triplicate on separate days. The MIC was taken to be the lowest concentration that 
completely inhibited the growth of bacteria, as detected by the unaided eye. The Minimum 
Bactericidal Concentrations (MBCs) were determined by withdrawing 10 µL from each well, 
transferring it onto a plate containing Mueller Hinton agar, and incubating overnight at 37 °C. 
MIC and/or MBC values were considered as different if they varied by more than one dilution.33 
Statistical Analysis 
Statistical analysis was carried out using Minitab® 16 software. Data was analyzed using analysis 
of variance (ANOVA) with Tukey’s multiple comparison test, and two-sample Student t tests. A 
p-value of ≤ 0.05 was considered significant. 
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Results and Discussion 
Production of Amorphous Solid Dispersions 
A number of binary solid dispersions of CIP with different polymers, in various concentrations, 
were produced by ball milling. Ball milling was previously found to be a suitable method for 
forming the amorphous CIP/succinic acid 2:1 salt, as it did not result in any degradation of the 
drug.2 The first polymer to be used was PVP, in a concentration range of 10–95% (w/w). PVP 
was chosen as it is a neutral, amorphous polymer, which is commonly used to produce ASDs  of 
poorly soluble drugs.16 Interestingly, CIP did not become amorphous when milled with any 
concentration of PVP tested. As the ratio of polymer to drug increased, the intensity of the peaks 
seen in the PXRDs decreased (Figure SI.1). However, this was most likely due to a dilution 
effect. Although CIP may theoretically interact with PVP via hydrogen bonds, these interactions 
were evidently too weak to yield a fully amorphous solid dispersion. Similarly, when CIP was 
milled with 40% (w/w) Soluplus or PEG 4000, both neutral polymers, a crystalline product was 
obtained (Figure 2a). 
The next polymer chosen for milling with CIP was polyvinyl alcohol (PVA), whose hydroxyl 
group can act as both a hydrogen bond acceptor and donor. Following 4 hours of milling at room 
temperature with 40% (w/w) PVA, small peaks were still seen by PXRD (Figure 2a). Milling at 
room temperature can result in increased temperatures, and a subsequent increase in molecular 
mobility.34 This can induce nucleation and crystallization of amorphous material. The use of too 
low a concentration of polymer can also result in an unstable product.35 Therefore, a higher 
concentration of 60% (w/w) PVA, 6 hour milling time and milling temperature of 2–5 oC were 
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implemented. This resulted in a product which was almost fully amorphous, however very small 
peaks could still be detected at approximately 20 and 25 2θ degrees due to the presence of 
residual crystalline CIP (Figure SI.2). 
As polymers with neutral functional groups were ineffective at amorphizing CIP, it was 
hypothesized that perhaps a polymer with ionizable moieties is necessary for this. As discussed 
above, many salts of CIP have been produced using acidic counter ions, such as succinic acid. 
The secondary amine of CIP’s piperazine ring is ionized in these salts, and forms hydrogen 
bonds with the negatively charged carboxylate groups of the acid.2  Therefore, the processing of 
CIP with acidic polymers may be a suitable means of producing a stable amorphous formulation. 
Eudragit L100, Eudragit L100-55 and Carbopol 981 all contain carboxylic acid groups, and were 
the first acidic polymers to be used. As can be seen from Figure 2b, each of these polymers 
resulted in the formation of an X-ray amorphous solid dispersion when milled with CIP for 4 
hours at room temperature, at a concentration of 40% (w/w). While higher ratios of polymer 
were also successful, the use of lower quantities of the Eudragit polymers resulted in a partially 
crystalline product (Figure SI.3). Carbopol on the other hand still produced an ASD when used at 
a concentration of 20% (w/w).  
HPMCAS also contains acidic groups. The LG grade contains 5–9% acetyl and 14–18% 
succinoyl groups, and the MG grade 7–11% and 10–14% of each group respectively.26 However, 
when these were milled with CIP using the same conditions as for the other acidic polymers, the 
product was only partially amorphous (Figure 2a). Higher concentrations of polymer and longer 
milling times still resulted in partially crystalline systems, as evidenced by PXRD peaks, 
although polymer concentration appears to have a greater effect on the crystallinity of these 
samples than milling time (Figure SI.4). Milling was next conducted at 2–5 oC, with a 60 % 
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(w/w) concentration of HPMCAS, for 6 hours. These conditions resulted in the formation of X-
ray amorphous solid dispersions (Figure 2b). 
 
 
 
 
Figure 2. (a) PXRD analysis following milling of CIP with various polymers at a 40% (w/w) 
concentration, for 4 hours at room temperature. (b) PXRD analysis of CIP and CIP ASDs. The 
peak at 25.3 2θ degrees corresponds to the major slip plane in the crystal lattice of CIP, and 
therefore it is the most likely peak to be present following mechanical stress of the drug.1 
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ASDs formed from the five acidic polymers discussed above (i.e. Eudragit L100, Eudragit L100-
55, Carbopol 981, HPMCAS-LG and HPMCAS-MG) were chosen for further examination. 
While a higher proportion of polymer should increase the physical stability of an ASD,36 it also 
necessitates the use of a larger preparation in order to deliver the required dose as an oral solid 
dosage form. This could result in problems with patient acceptability and compliance. Therefore, 
a polymer concentration of 40% (w/w) was chosen for the ASDs containing Eudragit L100, 
Eudragit L100-55 and Carbopol, and 60% (w/w) for those containing HPMCAS.  
Solid State Characterization of Amorphous Solid Dispersions 
The FTIR spectra of the ASDs, polymers and crystalline CIP are shown in Figure 3. The spectra 
of the physical mixtures (PMs) are also shown for comparison.  
In the spectra of each of the polymers, a peak can be seen between 1709 and 1744 cm-1 due to the 
C=O stretch of their carboxylic acid groups. A matching peak is present in the spectra of the 
PMs. The spectrum of crystalline CIP contains a peak at 1590 and 1375 cm-1, corresponding to 
the asymmetric and symmetric vibrations of the carboxylate ion, respectively.37 The peak at 1590 
cm-1 is absent from the spectra of the ASDs containing Eudragit and Carbopol, while those 
containing HPMCAS display a small peak, due to the presence of a residual amount of 
zwitterionic CIP. Interestingly, with all of the ASDs a strong peak is seen between 1723 and 
1734 cm-1, due to the C=O stretch of COOH. In each case, this peak is far more intense than the 
corresponding peak in the spectra of the PMs. Therefore, these peaks can be assigned to the 
carboxylic acid of CIP, and it can be concluded that this group is uncharged in the ASDs. This is 
in contrast to the semi crystalline solid dispersions containing PVP and Soluplus, which also 
show the characteristic peaks of the ionized carboxylate group of CIP. These peaks are weaker 
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and broader in the more disordered CIP/PVA solid dispersion, as the proportion of crystalline 
CIP is greatly reduced. In addition, like the ASDs, this sample has a peak at approximately 1720 
cm-1, which confirms the presence of the protonated carboxylic acid group of CIP (Figure SI.5). 
The strongest peak in the spectrum of crystalline CIP, at approximately 1618 cm-1, can be 
assigned to the C=O stretch of the ketone carbonyl.37 This peak is shifted to 1628 cm-1 in the 
spectra of the ASDs, which may be due to changes in the hydrogen bonding of this group. This 
peak was also found to shift to 1627–1629 cm-1 when zwitterionic CIP was heated to its melting 
point, which results in the formation of the unionized form of the drug.1 When the carboxylic 
acid of CIP is unionized, an intramolecular hydrogen bond is formed between this ketone and the 
neighboring carboxylic acid.1 This hydrogen bond is also found in CIP salts, in which the 
carboxylic acid of CIP is also protonated.2 In contrast, no such shift in the ketone carbonyl peak 
is seen in the spectra of the semi-crystalline solid dispersions, as they contain zwitterionic CIP. 
In each of the ASD spectra a broad peak at 2400–2600 cm-1 can be assigned to the NH2
+ 
stretching vibrations of CIP.2 Therefore, the drug is in a similar ionization state in these ASDs as 
it is in crystalline salts formed using various acids, i.e. with a neutral carboxylic acid and 
positively charged secondary amine. This group most likely interacts with negatively charged 
carboxylate groups in the polymers, as was seen with CIP succinate salts.2 The pKa of the 
carboxylic acid of CIP has been reported as 6.16, while that of the piperazine amine is 8.62.38 
Given that the pKa values of the polymers vary from 5 to 6.0,
24–26,39 the pKa difference between 
the secondary amine of the drug and carboxylic acid of the polymers falls within the limits of salt 
formation of ≥ 2–3 in each case.40 Therefore, these formulations could be considered as 
amorphous polymeric drug salts. Amorphous drug-polymer salts have also been produced by 
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Weuts et al,41 Song et al42 and Maniruzzaman et al.43 In each case an ionic interaction between 
the COOH groups of the polymers and amino groups of the drugs was detected. 
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Figure 3. FTIR spectra of ASDs and PMs containing (a) Eudragit L100 and Eudragit L100-55 
40% (w/w) (b) Carbopol 40% (w/w) and (c) HPMCAS-LG and HPMCAS-MG 60% (w/w). 
Conventional DSC, using a heating rate of 10 oC/min, resulted in DSC thermograms that proved 
difficult to interpret for these samples (Figure 4a). In each case it was impossible to pinpoint a 
definite glass transition temperature (Tg). Due to their high water content, the samples were first 
heated from 25–100 oC to allow for evaporation of sorbed water. 
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Figure 4. (a) Conventional DSC thermograms of CIP and CIP ASDs. The thermograms of the 
ASDs are those obtained from the second heating cycle, following initial heating to 100 oC to 
allow for water evaporation. (b) Heat flow traces from temperature modulated DSC (StepScan). 
Solid lines: specific heat curves; dotted lines: isokinetic baseline curves. The arrows point to the 
location of the Tg’s. The Tg’s obtained using the StepScan method as well as those calculated 
using the Gordon-Taylor (G-T) equation are also listed. 
Crystalline CIP has a melting point of approximately 272 oC, which is accompanied by 
degradation. The ASDs did not display a clear melting endotherm, which can be taken as 
confirmation of their amorphous nature.44 Like the pure drug, the ASDs undergo thermal 
degradation, as shown by TGA (Figure SI.6). All of the ASDs initially underwent water 
evaporation, followed by substantial degradation above ~ 230 oC, leading to a total mass loss of 
14–19%. 
Temperature-Modulated DSC (StepScan) was used to locate the Tg’s of the ASDs, and these are 
listed in Figure 4b. No crystallization in the temperature range 80–170 C was detected using the 
StepScan method, as can be seen from the isokinetic baseline traces (Figure 4b). A single Tg was 
visible in the thermograms of all of the ASDs. This suggests that CIP is miscible with each of 
these polymers45 and that phase separation does not occur in the ASDs.15 Unfortunately, despite 
the use of the StepScan method, the Tg of the CIP/Carbopol ASD could not be detected. The Tg’s 
that were calculated using the Gordon-Taylor (G-T) equation are also shown in Figure 4b. The 
G-T equation is based on the assumption that the components form an ideal mixture, with 
additive free volumes, but without any strong interactions between the constituents.22,23 For all of 
the ASDs the Tg values obtained experimentally were higher than those predicted theoretically. 
This was also found to be the case for the amorphous polymeric salts produced by Weuts et al 
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and Song et al.41,42 Particularly large positive deviations of approximately 48 and 45 oC were 
obtained for the ASDs containing Eudragit L100 and L100-55, respectively.  The G-T equation 
is known to underestimate the Tg of salts due to their ionic bonds, and larger deviations are 
obtained with counterions that form stronger electrostatic interactions with the drug.46,47 
Therefore, the FTIR analysis and the higher than predicted Tg’s of these ASDs suggest that ionic 
interactions exist between CIP and the polymers. 
In contrast to the Eudragit-containing ASDs, the experimental and calculated Tg’s of the 
CIP/HPMCAS-MG ASD were very similar, differing by only 1 oC. This suggests that the drug 
and polymer are fully miscible and do not interact specifically with one another.48 Alternatively, 
the strength of the interactions formed between the drug and polymer may be equal in strength to 
the homomolecular interactions in the pure components.49 This formulation would therefore be 
expected to be less stable than the ASDs containing Eudragit L100 or L100-55. A larger 
deviation of 7.5 oC was seen with CIP/HPMCAS-LG, suggesting that the drug interacts more 
substantially with this grade of HPMCAS, but less so than with the Eudragit polymers, possibly 
due to a larger content of succinoyl groups in this grade of HPMCAS. Similarly, stronger drug-
polymer interactions may exist in the Eudragit-containing ASDs due to the higher proportion of 
carboxylic acid groups present in these polymers in comparison to HPMCAS (see polymer 
structures in Figure SI.7). This may explain why it was more difficult to amorphize the 
CIP/HPMCAS mixtures, with larger polymer concentrations, longer milling times and lower 
temperatures being required compared to the other ASDs. 
Stability Studies 
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DVS analysis showed that all of the ASDs are capable of sorbing a large amount of water. At 
90% RH, a change in mass of between 16 and 20% was seen for all of the samples. CIP/Eudragit 
L100 sample sorbed the greatest amount of water, and CIP/HPMCAS-MG the least. The 
sorption-desorption isotherms obtained with all of the samples had a similar sigmoidal shape and 
hysteresis (Figure 5). These results are to be expected, as amorphous drugs are more hygroscopic 
than their crystalline forms. Water can absorb into the internal structure of amorphous materials 
rather than just adsorb to the surface.50 The presence of hygroscopic polymers would also have 
contributed to the water uptake of the ASDs. 
Water sorption can negatively affect drug stability by increasing the rate of crystallization. This 
is due to a lowering of the Tg, increase in molecular mobility and plasticization by moisture.
50 
However, all of the ASDs studied here remained amorphous following DVS analysis, as shown 
by PXRD (Figure SI.8). Electrostatic forces between the amino group of CIP and carboxylic acid 
of the polymers most likely stabilized the ASDs and prevented their crystallization during the 
study. Similar interactions were responsible for the improved stability of loperamide-polyacrylic 
acid and lapatinib-hydroxypropylmethylcellulose phthalate ASDs during stability studies.41,42 In 
addition, the long chains of polymers can delay crystallization by sterically hindering the 
diffusion of drug molecules, blocking sites of crystal growth, and increasing the kinetic barrier to 
nucleation.36,49 
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Figure 5. DVS analysis of CIP ASDs containing (a) Eudragit L100, Eudragit L100-55 and 
Carbopol 40% (w/w) and (b) HPMCAS-LG and HPMCAS-MG  60% (w/w). 
All of the ASDs, except for CIP/Eudragit L100, began to crystallize after 24 hours in accelerated 
storage conditions of 40 oC/75% RH. However, by day 3 of the study, this sample also began to 
show small crystallization peaks (Figure 6a). There was only a slight increase in the intensity of 
the bands seen in the PXRD of the HPMCAS samples between day 1 and 14, and no noticeable 
change in the Carbopol sample during the same timeframe (Figures 6b and c). As CIP/Eudragit 
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L100 did not show prominent peaks until day 3 of the study, it is therefore slightly more resistant 
to crystallization than the other ASDs. After 14 days, all of the samples were partially crystalline 
by PXRD, displaying a number of low intensity peaks. Therefore, although the ASDs were 
physically stable under the high humidity conditions of DVS, when this was combined with high 
temperature, a small degree of crystallization occurred. All of the ASDs, except for 
CIP/Carbopol, showed PXRD peaks corresponding to that of hydrated CIP, in particular the most 
characteristic peak of the 3.7 hydrate at approximately 6.5 2θ degrees.51 Peaks corresponding to 
the 3.1 hydrate (see next section) were also identified. In contrast to the other ASDs, the peaks of 
hydrated CIP were absent from the diffractograms of the CIP/Carbopol ASD, which instead 
showed broad peaks corresponding to anhydrous zwitterionic CIP. 
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Figure 6. PXRD analysis of ASDs stored at 40 oC/75% RH for 1, 3 and 14 days: (a) 
CIP/Eudragit L100 and CIP/Eudragit L100-55 (b) CIP/Carbopol and (c) CIP/HPMCAS-LG and 
CIP/HPMCAS-MG. The arrows identify the most prominent peaks, corresponding to CIP, CIP 
3.7 hydrate (3.7) and CIP 3.1 hydrate (3.1). 
Dynamic Solubility Studies 
As previously mentioned, CIP is a zwitterionic compound, with a basic and an acidic group that 
can ionize depending on the pH of the solvent. Therefore, it is important to study the solubility of 
this drug in different media in order to estimate how it will behave in various sections of the 
gastrointestinal tract.52 Solubility studies were carried out in water, FaSSIF (fasted state 
simulated intestinal fluid, pH 6.5) and FaSSGF (fasted state simulated gastric fluid, pH 1.6). Due 
to excessive clumping and the viscous nature of the solutions formed when the CIP/Eudragit 
L100-55 and Carbopol samples were added to the media, it was not possible to accurately carry 
out solubility tests on these ASDs.  
CIP has low aqueous solubility, achieving a concentration of only 0.09 mg/mL in water after 2 
hours. The Eudragit and HPMCAS ASDs showed superior solubility, obtaining concentrations 
approximately 7 and 19 times that of the pure drug, respectively, in the same time frame. After a 
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steep initial increase in concentration within the first 10 minutes or so, these levels were then 
sustained for the duration of the experiment (Figure 7a). All three of these polymers are 
practically insoluble in water,26,27 which may have limited their ability to improve the aqueous 
solubility of CIP. Although the LG grade of HPMCAS resulted in slightly higher drug 
concentrations in the initial portion of the study, after 2 hours no statistically significant 
difference was seen when compared to the MG grade (p = 0.27). 
The solubility profiles of the ASDs are similar to the “spring” and “parachute” model described 
by Guzmán et al.18 Due to their disordered structure, ASDs enable the rapid dissolution of drugs 
and act as a “spring” for the formation of a supersaturated solution. Unfortunately, the high 
energy supersaturated state is usually short-lived, and amorphous drugs tend to quickly convert 
to more a stable and less soluble crystal form. This leads to precipitation of the API and reduced 
absorption in vivo. However, polymers which are present in the ASD can inhibit the nucleation 
and crystallization of the drug, decreasing the rate of precipitation.53 In this way they act as 
“parachutes”, helping to maintain supersaturation, and thus increase the rate and extent of drug 
absorption.18 The polymers present in the CIP ASDs appear to have played a similar role, 
enabling high concentrations of CIP to remain in solution for at least 2 hours. 
PXRD analysis of the excess solid recovered at the end of the studies confirms that a low 
proportion of CIP crystallized from the ASDs in solution overall (Figure SI.9). CIP/Eudragit 
L100 was quite resistant to crystallization in water, with just one small peak appearing in the 
PXRD of the excess solid recovered at the end of the study, at 6.5 2θ degrees. The HPMCAS 
ASDs showed a greater number of peaks, of higher intensity, but still remained somewhat 
disordered. As demonstrated in the stability study, these ASDs have a greater propensity to 
crystallize when exposed to water than those containing Eudragit L100. The excess solids 
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recovered at the end of the solubility studies in FaSSIF were also partially crystalline. A more 
crystalline product was obtained with CIP/HPMCAS-LG, indicating that this ASD is less 
resistant to crystallization at basic pH. Unlike the ASDs, pure crystalline CIP formed a fully 
crystalline hydrate in all media; however the PXRD pattern of the residue from solubility studies 
in water differed from those conducted in FaSSIF and FaSSGF (Figure SI.9d). In the latter two 
cases, the CIP 3.7 hydrate was indentified,51 while TGA of the former hydrate found it to contain 
14.3% water (Figure SI.10). This corresponds to approximately 3.1 moles of water per mole of 
CIP. Interestingly, while the HPMCAS-LG ASD also formed the 3.7 hydrate in water, all the 
other ASD/media combinations resulted in the CIP 3.1 hydrate. 
In FaSSIF crystalline CIP reached a peak concentration of 0.9 mg/mL after 1 min. This quickly 
fell over the first 10 min, and then remained fairly constant at approximately 0.15 mg/mL for the 
remainder of the study. The sodium taurocholate and lecithin present in FaSSIF mimic bile salts 
and phospholipids, respectively, in intestinal fluid.54 The increased solubility of the pure drug in 
this medium compared to water may be due to the presence of these surfactants. The Eudragit 
L100 and HPMCAS ASDs behaved differently over the course of the study. The solubility of the 
former increased gradually over 2 hours, giving the plot in Figure 7b a convex shape. In contrast, 
the HPMCAS-LG and HPMCAS-MG ASDs reached a peak in CIP concentration after 5–10 min, 
and then slowly fell over the remainder of the study. The LG grade of HPMCAS reached a top 
concentration of 1.9 mg/mL, whereas the MG grade obtained a maximum of 1.5 mg/mL. Solid 
dispersions containing different grades of HPMCAS would be expected to show discrepancies in 
solubility at various pH values, due to differences in their succinoyl and acetyl content.55 
However, although the former sample remained at a higher concentration for the majority of the 
study, after 2 hours an equal concentration of 1.3 mg/mL was obtained with both HPMCAS 
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ASDs. The decrease in the solubility of CIP/HPMCAS-LG over time may be due to the 
conversion of the drug to its hydrate, as detected by PXRD, as the aqueous solubility and 
dissolution rate of CIP hydrate is significantly lower than that of the anhydrous drug.56 Although 
HPMCAS-LG and HPMCAS-MG are soluble at a pH above 5.5 and 6.0 respectively,26 this did 
not result in a substantial increase in the solubility of these ASDs in FaSSIF. 
In FaSSGF the Eudragit L100 and HPMCAS-LG ASDs showed very similar behavior to each 
other, achieving maximum CIP concentrations of 3.2 mg/mL after 2 hours. The HPMCAS-MG 
formulation was somewhat more soluble at low pH, reaching 4.1 mg/mL (Figure 7c). The 
solubility of the pure drug however was approximately 3–4 times higher than that of the ASDs. 
This may be due to the fact that the polymers are insoluble in aqueous acidic solutions.55 CIP on 
the other hand has high solubility at pH < 5, as it has a net positive charge. In contrast, it has 
minimal solubility at neutral pH, where it bears no overall charge.4 Similar results were seen in 
solubility studies of malonic, tartaric and oxalic acid salts of CIP, which were also found to be 
less soluble in acidic media than the pure drug.10 An amorphous solid was recovered at the end 
of this study for all of the ASDs, indicating that they are resistant to crystallization at low pH.  
The pH of the solutions at the end of the studies was measured and is listed in Figure 7. Very 
small changes in pH, of ± 0.2 on average, occurred over the course of the study, with the 
exception of pure CIP in FaSSGF. In this case the high quantity of weakly basic drug in solution 
increased the pH to 4.7. Therefore, the differences in solubility described above cannot be 
attributed to changes in pH, but rather to the physical form of the drug and the presence of 
polymers. 
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Figure 7. Solubility studies in (a) water (b) FaSSIF and (c) FaSSGF at 37 oC. The average of at 
least 3 experiments are plotted, ± the standard deviation. The average pH of the solutions at the 
end of the study is also shown.  
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A modification of the Henderson-Hasselbalch equation was used to construct the theoretical pH-
solubility profile of pure CIP and the commercial hydrochloride salt, CIP HCl: 
ST = [B] (1 + 10
pKa1-pH + 10pH–pKa2)        (4) 
ST is the total solubility of the drug in moles/L and [B] is the concentration of the free base 
(approximately 0.000266 M for CIP and 0.0008 M for CIP HCl). As previously mentioned, the 
pKa values of the carboxylic acid (pKa1) and piperazine amine (pKa2) of CIP are equal to 6.16, 
and 8.62, respectively.38 The CIP ASDs may be considered as basic salts, as they consist of an 
interaction between the positively charged amino group of the drug and negatively charged 
carboxylate groups of the polymers. According to Kramer and Flynn, the pH-solubility profile of 
a basic salt can be represented by two independent solubility profiles, one of which describes 
when the free base is the saturation species, and the other when the salt is the saturation 
species.57 The point at which the two curves intersect is referred to as the pHmax, the pH of 
maximum solubility. In a saturated solution above pHmax, the dissolved solute is in equilibrium 
with the free base, and at a pH below pHmax, it is in equilibrium with the salt.
6 The following 
equation was used to predict the pH-solubility profile of the ASDs:6 
ST (pH<pHmax) = [BH
+]s (1 + 10
pH – pKa)        (5) 
[BH+]s is the concentration of the protonated amorphous salt. The subscript s highlights the fact 
that the salt is the saturation species at a pH below pHmax.
6 
As can be seen from Figure 8, the experimental data does not fit the theoretical pH-solubility 
curve of CIP exactly. The solubility of the drug from the ASDs in water and FaSSIF is higher 
than that predicted for CIP. These experimental data points align more closely with the profile of 
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CIP HCl. Therefore, a more accurate pHmax for these salts would be the intersection of the curve 
for CIP HCl and the CIP ASDs, which occurs at a pH of 5.1. The three main outliers in Figure 8 
correspond to the particularly high solubility of the ASDs in FaSSIF. As previously mentioned, 
FaSSIF contains surfactants, which may enhance the solubility of these solids compared to 
water. This lack of fit also suggests that the solubility enhancement of these formulations is not 
due to their effect on pH. Instead this may be attributed to their amorphous nature and polymer 
content. The solubility of the pure drug in FaSSGF is also higher than that predicted, and aligns 
more closely with the CIP HCl curve. Due to the presence of HCl in FaSSGF, the drug is likely 
to be in a similar environment in this medium as CIP HCl in water. At a pH below pHmax, i.e. in 
FaSSGF, the ASDs no longer follow the solubility curve of CIP, as the equilibrium species is 
now the salt. At acidic pH they may be more accurately described by eq 5 above. 
 
  
Figure 8. Theoretical pH-solubility profiles of CIP (black), CIP HCl (green), and CIP ASDs 
(blue).  The symbols represent the average concentrations obtained from solubility studies after 
two hours in water (filled symbols), FaSSIF (empty symbols) and FaSSGF (half-filled symbols). 
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The plot above shows the distribution of species for CIP, Eudragit L100 and HPMCAS as a 
function of pH (black lines: CIP; red line: Eudragit L100; and blue line: HPMCAS). 
PAMPA Permeability Study 
The results of the PAMPA study, under iso-pH and pH gradient conditions, are shown in Table 
1. The commercially available hydrochloride salt, CIP HCl, was included in the study for 
comparison. PAMPA is usually carried out using donor and acceptor solutions of the same pH 
(iso-pH conditions), however this does not accurately mimic what occurs in vivo. Fortuna et al 
obtained the best correlation between apparent permeability from PAMPA studies and human 
intestinal absorption for a range of drugs, including the fluoroquinolone norfloxacin, with a pH 
of 6.5 and 7.4 in the donor and acceptor compartments, respectively.58 The pH of the blood and 
the cytosol of intestinal cells lining the duodenum is about 7.4, therefore this is a suitable pH to 
use for the acceptor compartment.59 CIP is believed to be absorbed from the upper section of the 
duodenum, which has a pH of 6.4.60,61 A donor/acceptor pH of 6.4/7.4 was therefore chosen for 
this study in order to more closely represent the pH gradient present in vivo at the site of CIP 
absorption.59 In addition, as the permeability of ionizable drugs, such as CIP, depends on pH, it 
is useful to carry out PAMPA at two different pH values for such compounds, to prevent under- 
or overestimation of permeability.  
Table 1. PAMPA Permeability Values of CIP 
 iso-pH pH gradient 
p-valueb Sample Pe
a x 106 
(cm/s)  
log Pe Pe x 10
6 
(cm/s) 
log Pe 
Crystalline 0.56 ± 0.06 -6.25 ± 0.05 0.62 ± 0.08 -6.21 ± 0.05 0.42 
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CIP 
CIP HCl 0.32 ± 0.00 -6.50 ± 0.01 0.32 ± 0.01 -6.49 ± 0.01 0.22 
CIP/Eudragit 
L100 
0.52 ± 0.00 -6.28 ± 0.00 0.50 ± 0.06 -6.31 ± 0.05 
0.50 
CIP/HPMCAS
-LG 
0.75 ± 0.06 -6.13 ± 0.04 0.64 ± 0.10 -6.20 ± 0.07 
0.20 
CIP/HPMCAS
-MG  
0.64 ± 0.03 -6.19 ± 0.02 0.67 ± 0.03 -6.18 ± 0.02 
0.34 
aPe: effective permeability. The average of three measurements is shown, ± the standard 
deviation. bp-value from t test comparing Pe from regular and pH-gradient PAMPA. 
 
According to Sugano, a permeability of less than 1 × 10−6 cm/s (or log Pe < -6) can be considered 
as low permeability.62 As can be seen from Table 1, all of the samples are poorly permeable, 
with a Pe < 1 × 10
−6 cm/s. A similarly low Pe of 0.19 x 10
-6 cm/s for CIP was obtained by Tehler 
et al in Caco-2 studies.63 Two-sample t tests were used to compare the results of the individual 
samples under both pH conditions, and in each case no statistically significant difference was 
found (see p-values in Table 1). The pI of CIP is around 7.4–7.5.64 The passive absorption of this 
drug would therefore be expected to be highest at this pH. As the pH is decreased below the pI, 
the carboxylate group of CIP will become protonated, and the proportion of drug bearing an 
overall positive charge will increase. This should reduce its passive transport through a lipid 
membrane. However, at neutral pH the drug exists primarily as the zwitterion, with only about 
2% expected to be present in the unionized form at the pI.64 While the membrane penetration and 
diffusion of unionized CIP is energetically favorable, the transmembrane translocation of 
zwitterionic CIP is unlikely to occur.65 Evidently, dropping from pH 7.4 to 6.4 does not have a 
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large effect on the proportion of unionized CIP present, and thus no significant difference in Pe 
was seen when the donor solution pH was changed in the above study. 
ANOVA and Tukey’s multiple comparison test were carried out to compare the Pe of the 
different samples. CIP from ASDs containing HPMCAS-LG and HPMCAS-MG possessed the 
highest permeability, with a Pe of 0.75 × 10
−6 and 0.64 × 10−6 cm/s, respectively under iso-pH 
conditions, and 0.64 × 10−6 and 0.67 × 10−6 cm/s, respectively, with a pH-gradient; however 
these samples were not statistically significantly different from each other under either pH 
condition. In addition, the CIP/HPMCAS-MG system did not differ significantly from the pure 
drug in either study, while CIP from the HPMCAS-LG sample was only significantly more 
permeable than CIP under iso-pH conditions. CIP as the HCl salt on the other hand had a 
significantly lower permeability than the other samples, with a Pe of 0.32 × 10
−6 cm/s under both 
pH conditions. The drug from the ASD containing Eudragit L100 had a slightly lower average Pe 
than the pure crystalline drug in both PAMPA experiments; however this difference was not 
statistically significant. The lower Pe obtained with the CIP/Eudragit L100 ASD compared to 
those containing HPMCAS may be due to the formation of drug/polymer complexes in solution. 
As shown previously by Friesen et al, upon addition to aqueous solutions, ASDs may rapidly 
disperse to form a number of species.66 These can potentially include large drug/polymer 
aggregates, which may form a slowly dissolving amorphous precipitate, and thus reduce the 
concentration of free drug in solution.66 This would be more likely to occur with CIP/Eudragit 
L100 due to the stronger drug-polymer interactions present in this ASD, as suggested by its 
particularly high Tg. 
A number of studies have found that other solubility enhancing formulations such as 
cyclodextrins, surfactants and cosolvents decrease the permeability of drugs in both PAMPA and 
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intestinal perfusion assays, leading to a trade-off between solubility and permeability.21,67 
According to Miller et al, preparations such as these increase the equilibrium solubility of drugs, 
which results in a decrease in their apparent cell membrane/intestinal lumen partition coefficient. 
As the permeability of a drug is directly related to this coefficient, the solubility advantage 
provided by these formulations is accompanied by a decrease in permeability.67 In contrast, 
ASDs increase the solubility of drugs via supersaturation, which does not affect the apparent 
membrane/lumen partition coefficient. Amorphous formulations can therefore significantly 
increase the concentration of drug in solution, while also maintaining a constant effective 
permeability, giving them a superior solubility-permeability balance.21,67 The results of this study 
are therefore in line with those of other researchers, with all of the CIP ASDs enhancing the 
solubility of the drug in water and FaSSIF, without a subsequent decrease in permeability. The 
crystalline CIP HCl salt on the other hand significantly reduced the permeability of the drug, 
most likely due to greater ionization of CIP. Although the Pe of a drug is not affected by its 
concentration (as long as the drug is free to pass through the membrane), the increased solubility 
afforded by ASDs should increase the transmembrane flux of a drug, and thus may also improve 
its in vivo absorption.67  
According to Tam et al, 18% of CIP is absorbed via the paracellular route at pH 6.5.68 As the 
PAMPA model does not take account of paracellular transport, it is possible that the results 
above underestimate the in vivo absorption of CIP. PAMPA is also unable to predict active 
transport, and will therefore underestimate the permeability of compounds which are absorbed 
via drug transporters.69 This could explain why the effective permeability of CIP reported here is 
lower than that obtained by others in rat in situ and Caco-2 cell studies.68,70 While CIP is mainly 
absorbed by passive transport, it is also a substrate for active transporters in the intestine, such as 
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organic anion transporting polypeptide 1A2 (OATP1A2).71 In addition, it is a substrate for the 
efflux protein breast cancer resistance protein (BCRP), which reduces the bioavailability of the 
drug.72 Despite this, Bermejo et al showed that for fluoroquinolones such as CIP, there was a 
good correlation between the results of PAMPA and that of Caco-2 and  rat in situ permeability 
studies.38 As the main aim of the permeability assay performed in this study was to determine 
whether ASD formation affects the permeability of CIP, PAMPA was suitable for this 
comparative analysis. However, in order to obtain a more accurate quantitative estimate of the 
permeability of the drug and ASDs, more representative permeability studies would be required, 
such as rat in situ perfusion assays, which more closely mimic the environment in vivo. 
Bacterial Studies 
The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) 
of CIP and the ASDs in a number of bacterial species are shown in Table 2. The values that 
differ significantly from those of pure crystalline CIP are shown in bold. The MBC is expected 
to be larger than the MIC, as a larger quantity of API is required to kill bacteria rather than just 
inhibit their growth. MICs ≤ 1.0 µg/mL indicate that the microorganism is susceptible to CIP, 
whereas MICs ≥ 2.0 µg/mL indicate resistance to this antibiotic.73 All of the organisms used in 
this study can therefore be considered as sensitive to CIP, with MICs ≤ 1 µg/mL. The MIC and 
MBC values obtained with CIP are close to  those obtained by other researchers in these 
species.74–76 E. coli was found to be the most susceptible strain to CIP, with a MIC of 0.008–
0.032 µg/mL. This was followed by K. pneumoniae (MIC 0.032–0.125 µg/mL), P. aeruginosa 
(MIC 0.125–1.0 µg/mL) and S. aureus (MIC 0.25–1.0 µg/mL). The MBCs also followed the 
same order of susceptibility. A drug is generally considered bactericidal if it has a MBC to MIC 
ratio of ≤ 4.77 Therefore, all of the samples in this study were bactericidal, with ratios of 1–2. 
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The formulation of CIP as an ASD did not result in a decrease in antibacterial activity in any 
case. In fact, CIP/ HPMCAS-MG had a significantly lower MIC and MBC in all bacterial 
species studied compared to the pure drug. The MIC of HPMCAS-LG was also significantly 
improved in E. coli, while its MBC decreased in both E. coli and S. aureus. As described above, 
these ASDs had the highest Pe in PAMPA permeability studies, whereas CIP/Eudragit L100 did 
not differ significantly from the pure drug. Therefore, the improved permeability of these 
samples may have aided the penetration of CIP into the bacterial cells, most likely via the 
passive diffusion route through the cell membranes. 
Table 2. Minimum Inhibitory Concentration and Minimum Bactericidal Concentration of 
Ciprofloxacin and ASDs in Various Bacteria 
Sample S. aureus E. coli P. aeruginosa K. pneumoniae 
Minimum Inhibitory Concentration (µg/mL) 
CIP 1 0.032 0.5 0.125 
CIP/Eudragit L100 1 0.032 0.5–1 0.125 
CIP/HPMCAS-LG 0.5 0.008–0.016 0.25–0.5 0.063–0.125 
CIP/HPMCAS-MG 0.25–0.5 0.008–0.016 0.125–0.25 0.032–0.063 
Minimum Bactericidal Concentration (µg/mL) 
CIP  1.0–2.0 0.032–0.064 1.0 0.25 
CIP/Eudragit L100 1 0.032 1.0 0.25 
CIP/HPMCAS-LG 0.5 0.016 1.0 0.125 
CIP/HPMCAS-MG 0.5 0.016 0.25–0.5 0.063–0.125 
 
Conclusions  
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Amorphous solid dispersions are one formulation option for poorly soluble drugs, however the 
polymers used in these preparations must be carefully chosen. This work has shown that an 
acidic polymer is necessary to produce CIP ASDs by ball milling, as it enables the formation of 
stabilizing ionic interactions between the two components. These bonds resulted in high Tg 
values, above those predicted by the Gordon-Taylor equation. While the CIP ASDs crystallized 
quickly under accelerated stability conditions of 40 oC/75% RH, they remained amorphous 
following exposure to humidity levels of up to 90% at 25 oC during DVS analysis. Therefore, 
although the stabilizing effects of the polymers were not sufficient to prevent crystallization of 
CIP when exposed to a combination of high heat and humidity, these ASDs could be expected to 
remain stable if stored at ambient temperatures.  
The ASDs chosen for further examination showed superior solubility in water and FaSSIF 
compared to the pure drug, which can be attributed to their amorphous nature, rather than any 
effect on pH. The polymer content of the ASDs also enabled the maintenance of supersaturation 
for at least two hours in most cases. In addition, no decrease in the passive permeability of CIP 
occurred with any of these ASDs, while a modest increase in effective permeability was seen 
with the ASD containing HPMCAS-LG. In contrast, the crystalline CIP HCl salt significantly 
decreased the permeability of the drug, highlighting the benefit of amorphous polymeric 
formulations in this regard. In line with the results of the permeability assay, the formulation of 
CIP as an ASD did not reduce its antibacterial potency in the bacterial species studied, and a 
decrease in MIC and MBC was also obtained with the ASDs containing HPMCAS. This 
indicates that ASD formation with HPMCAS increases the proportion of CIP capable of 
diffusing through bacterial cell membranes. Therefore, ASDs may be a viable alternative for 
formulating CIP with improved solubility, bioavailability and antibacterial activity. 
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Supporting Information. 
PXRD and FTIR analysis of semi-crystalline solid dispersions; TGA of CIP and ASDs; chemical 
structure of polymers; PXRD analysis following DVS and solubility studies; and TGA of CIP 
hydrate. This material is available free of charge via the Internet at http://pubs.acs.org. 
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